The recently released 2017-18 annual report of the Canadian Cancer Clinical Trials Network (3CTN) summarizes the accomplishments of the 3CTN cancer centres and represents the culmination of its initial four year strategic plan spanning 2014-2018. The report provides many examples of how 3CTN has established a sustained framework for supporting Canada’s academic cancer clinical trials environment, setting a foundation for the future.
The University of Toronto’s Dalla Lana School of Public Health will be the new scientific partner of Canadian Partnership for Tomorrow Project (CPTP), Canada’s largest-ever health research platform. The University of Toronto, working in partnership with the Ontario Institute for Cancer Research, will accelerate CPTP’s research potential and provide more opportunities for made-in-Canada discoveries. The Dalla Lana School of Public Health was selected for its strong track record of world class public health and extensive experience leading large-scale studies.
Coordinated nationally through the Canadian Partnership Against Cancer and now the Dalla Lana School of Public Health, CPTP is the result of a decade of collaboration among scientific leaders across the country: BC Generations Project, Alberta’s Tomorrow Project, Ontario Health Study, Quebec’s CARTaGENE project, Atlantic PATH, and CPTP’s newest emerging cohort, the Manitoba Tomorrow Project. The new leadership team, Dr. Philip Awadalla as National Scientific Director and John McLaughlin as Executive Director, is committed to continuing the unprecedented pan-Canadian collaboration among the regional cohorts.
With health and biological information from over 300,000 Canadians aged 30 to 74, CPTP will remain a valuable international and national research tool, allowing scientists to further explore how genetics, environment, lifestyle and behaviour interact and contribute to the development of cancer and other chronic diseases. For more information, see http://www.partnershipfortomorrow.ca/.
According to CCRA's latest report, $480M was invested in cancer research in 2015. The investment in operating grants accounted for a larger proportion of the investment than in previous years due to a decline in investment in equipment/infrastructure. There were significant increases from 2011 to 2015 in the investments made in research on prostate cancer, brain cancer, Non-Hodgkin lymphoma and leukemia.
To access this report, detailed tables, and a companion slide deck, click here.
*Please note that a regrettable error was made on the initial PDF and the hard copy version of the English report. The Breast Cancer Society of Canada (BCSC) was omitted from the list of member organizations on the final page of the report. The PDF has been corrected and uploaded (Jan. 29/18). BCSC is a valued member and we apologize for this omission.
On December 29, 2017, Her Excellency the Right Honourable Julie Payette, Governor General of Canada, announced new appointments to the Order of Canada. Among them, is Dr. Elizabeth Eisenhauer, who is appointed as an Officer of the Order of Canada. Dr. Eisenhauer is being recognized for her extensive research contributions and leadership within the field of clinical cancer care in Canada. We applaud this well-deserved recognition!